Artivion's stock experienced a significant 24-hour plunge of 13.10% during Thursday's trading session, reflecting a sharp negative reaction from investors.

The decline followed the company's first-quarter earnings release and concurrent announcements that prompted a downward revision of its financial outlook. Artivion lowered its full-year 2026 revenue guidance to a range of $480 million to $496 million, down from its previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA outlook to $100 million to $107 million.

Investor sentiment was further impacted by Artivion's disclosure of plans to acquire Endospan, the developer of the recently FDA-approved NEXUS Aortic Arch System. The acquisition involves a base purchase price of $175 million, with Artivion electing to pay entirely in cash, resulting in a net purchase price of approximately $135 million. Additionally, the company could pay up to $200 million in contingent consideration based on the future performance of Endospan's product. Management indicated that U.S. revenue from the NEXUS system is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious annual forecast.